Diphenhydramine and Sweating

• Status: Recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

In 2012, it was estimated that nearly 1 in 4 Canadians suffer from allergic rhinitis. To add, 78% of individuals working in predisposing environments are predicted to develop occupational rhinitis. Currently, the most popular treatment for rhinitis is antihistamine medication such as diphenhydramine, a first-generation antihistamine sold commercially as Benadryl®. Due it its anticholinergic effects, diphenhydramine has been suggested to impair the whole body sweating response during heat stress, potentially leaving consumers at an increased risk of heat-related illness. This randomized control trial approved by Health Canada will investigate whether ingesting extra strength diphenhydramine (50mg) will alter whole-body sweat losses during 60 minutes of exercise.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Lakehead University
• Treatments: Diphenhydramine; Promethazine

Criteria

Inclusion Criteria:

• Able to safely perform ~60 minutes of moderate intensity exercise

• No known hypersensitivity to diphenhydramine

• Not on any prescribed medication

• Body-mass index (BMI) less than 30

Exclusion Criteria:

• Outside 18 - 49 years of age

• Diagnosed with any cardiovascular, respiratory, neurological or metabolic disease

• History of any cardiovascular, respiratory, neurological or metabolic disease

• Unable to exercise for 60 minutes at moderate intensity, or have a musculoskeletal injury

• BMI > or = 30